{"gene":"TP53","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2010,"finding":"USP10, a cytoplasmic ubiquitin-specific protease, deubiquitinates p53, reversing Mdm2-induced p53 nuclear export and degradation. After DNA damage, ATM-mediated phosphorylation of USP10 at Thr42 and Ser337 stabilizes USP10 and triggers a fraction of USP10 to translocate to the nucleus to activate p53.","method":"Co-immunoprecipitation, in vitro deubiquitination assay, site-directed mutagenesis, subcellular fractionation, kinase assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, in vitro assay, mutagenesis, fractionation) in a single rigorous study published in Cell","pmids":["20096447"],"is_preprint":false},{"year":2016,"finding":"NAT10 acetylates p53 at K120 and stabilizes p53 by counteracting Mdm2. Additionally, NAT10 promotes Mdm2 degradation via its intrinsic E3 ubiquitin ligase activity. After DNA damage, NAT10 translocates from the nucleolus to the nucleoplasm to activate p53-mediated cell cycle control and apoptosis.","method":"Co-immunoprecipitation, in vitro acetylation assay, ubiquitination assay, subcellular fractionation, loss-of-function experiments","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (Co-IP, in vitro enzymatic assays, localization) in single lab study","pmids":["26882543"],"is_preprint":false},{"year":2005,"finding":"The human p53 gene contains an alternative promoter in intron 3 and produces multiple splice variant isoforms. The p53beta isoform can bind differentially to promoters and enhance p53 target gene expression in a promoter-dependent manner, while Delta133p53 acts as a dominant-negative inhibitor of full-length p53, suppressing p53-mediated apoptosis.","method":"Reporter gene assay, promoter binding assay, apoptosis assay, RT-PCR, tissue expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional assays (reporter, binding, apoptosis) with isoform-specific constructs, replicated across multiple experimental systems","pmids":["16131611"],"is_preprint":false},{"year":2019,"finding":"p53 is modified by beta-hydroxybutyrylation (Kbhb) at lysines 120, 319, and 370, catalyzed by CBP. This modification results in lower levels of p53 acetylation, reduced expression of p53 downstream genes p21 and PUMA, and reduced cell growth arrest and apoptosis under p53-activating conditions.","method":"Mass spectrometry, in vitro modification assay, Western blot, gene expression analysis, cell viability assay, mouse tissue analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (MS, in vitro assay, cellular and in vivo readouts) in single lab study","pmids":["30858356"],"is_preprint":false},{"year":2003,"finding":"p29ING4 and p28ING5 physically interact with both p53 and p300 (a histone acetyltransferase), enhance p53 acetylation at Lys-382, activate the p21/WAF1 promoter, and induce apoptosis in a p53-dependent manner.","method":"Co-immunoprecipitation, reporter gene assay, Western blot, apoptosis assay, colony formation assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional assays (reporter, apoptosis) in single lab study","pmids":["12750254"],"is_preprint":false},{"year":2001,"finding":"p53DINP1 is a p53-inducible gene whose protein product forms a complex that phosphorylates p53 at Ser46. Antisense inhibition of p53DINP1 blocks DNA damage-induced Ser46 phosphorylation, p53AIP1 induction, and apoptosis. Overexpression of p53DINP1 synergistically enhances Ser46 phosphorylation and apoptotic cell death with DNA damage.","method":"Differential display, antisense oligonucleotide knockdown, kinase assay, co-immunoprecipitation, apoptosis assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — kinase assay establishing phosphorylation, combined with loss-of-function (antisense) and gain-of-function experiments with defined readouts","pmids":["11511362"],"is_preprint":false},{"year":2014,"finding":"USP11, an ubiquitin-specific protease, forms specific complexes with p53 and stabilizes p53 by deubiquitinating it. Down-regulation of USP11 dramatically attenuates p53 induction in response to DNA damage stress.","method":"Co-immunoprecipitation, ubiquitination assay, Western blot, siRNA knockdown","journal":"Journal of Zhejiang University. Science. B","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — Co-IP and functional knockdown from single lab, limited mechanistic detail in abstract","pmids":["25471832"],"is_preprint":false},{"year":2018,"finding":"TP53 functions as a pioneer transcription factor with binding limited to nucleosome edges; significant binding inhibition occurs within 50 bp of the nucleosome dyad. Binding site affinity affects TP53 binding only at equivalent nucleosomal positions; otherwise, nucleosome position takes precedence. TP53 has strong nonspecific nucleosome binding facilitating chromatin interaction.","method":"Competitive in vitro nucleosome binding assay, next-generation sequencing, cell line ChIP validation","journal":"Genome research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with quantitative sequencing readout plus in-cell validation, single lab but orthogonal methods","pmids":["30409772"],"is_preprint":false},{"year":2016,"finding":"The p53 isoform Delta133p53beta promotes cancer cell invasion and epithelial-mesenchymal transition (EMT) regardless of full-length TP53 mutation status. Endogenous mutant Delta133p53beta depletion prevents invasiveness without affecting full-length mutant p53 expression.","method":"siRNA knockdown, invasion assay, EMT marker analysis, clinical correlations","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific knockdown with defined invasion phenotype, validated in multiple cell lines and clinical data","pmids":["27630122"],"is_preprint":false},{"year":2001,"finding":"Deoxycholic acid (DCA) suppresses p53 protein levels by stimulating proteasome-mediated p53 degradation. This process requires nuclear export via CRM1 and is mediated in part through ERK signaling, as ERK pathway blockade (but not PKC blockade) prevents DCA-induced p53 suppression.","method":"Proteasome inhibitor (lactacystin), nuclear export inhibitor (leptomycin B), ERK/PKC pathway inhibitors, Western blot, reporter assay","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with multiple specific inhibitors establishing pathway mechanism, single lab","pmids":["11375905"],"is_preprint":false},{"year":2021,"finding":"TP53 transcriptionally induces FBXO22, which ubiquitinates KDM4B (complexed with MYC-NCOR1 suppressors) for degradation, leading to transcriptional induction of TFEB and upregulation of basal autophagy. AKT1 activation counteracts this process through phosphorylation of KDM4B, inhibiting FBXO22-mediated ubiquitination.","method":"ChIP-seq, ubiquitination assay, genetic knockout (fbxo22 mice), overexpression studies, co-immunoprecipitation","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including in vivo model, ChIP-seq, and ubiquitination assay in single lab","pmids":["33706682"],"is_preprint":false},{"year":2022,"finding":"At the onset of senescence, TP53 activation leads to downregulation of TRF2 at pericentromeres, which triggers ATM-mediated DNA breaks, heterochromatin decondensation (release of KAP1 and Lamin B1), recombination, satellite DNA excision, and interferon response activation. This TP53-TRF2 axis drives selective pericentromeric heterochromatin dismantling during senescence.","method":"Live cell imaging, ChIP, DNA damage assays, fractionation, cytosolic DNA detection (cGAS), genetic epistasis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis and multiple mechanistic readouts in single lab establishing pathway order","pmids":["35819196"],"is_preprint":false},{"year":2023,"finding":"A rare African-specific TP53 germline variant Y107H is structurally similar to wild-type p53 (by NMR and crystal structure) but is selectively impaired for transactivation of a small subset of target genes including PADI4. PADI4 is itself tumor suppressive and requires an intact immune system for tumor suppression, defining a p53-PADI4 immune-modulatory tumor suppression axis.","method":"NMR spectroscopy, X-ray crystallography, transactivation assays, mouse tumor models, colony suppression assay","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus NMR plus functional transactivation assays plus in vivo mouse tumor models establishing a specific mechanistic pathway","pmids":["37140445"],"is_preprint":false},{"year":2021,"finding":"TP53-dependent activation of p53 in adipocytes facilitates exosome and protein secretion (including FABP4 and AdEV proteins) in response to lipolytic stimulation and genotoxic stress. Pharmacologic inhibition or genetic loss of p53 attenuates adipocyte-derived extracellular vesicle and protein secretion.","method":"p53 inhibitor treatment, MDM2 antagonist (nutlin) activation, p53-/- mouse model, mass spectrometry of secretome, Western blot","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (p53-/- mice) and pharmacological (nutlin, inhibitor) approaches with mass spectrometry validation in single lab","pmids":["37347719"],"is_preprint":false},{"year":2021,"finding":"TP53 loss enables cancer cell lineage plasticity from AR-dependent luminal epithelial to AR-independent basal-like cells in prostate cancer, mediated through increased SOX2 expression. Restoring TP53 function (together with RB1) or inhibiting SOX2 reverses this lineage plasticity and enzalutamide resistance.","method":"In vitro and in vivo prostate cancer models, TP53/RB1 restoration, SOX2 knockdown, lineage marker analysis","journal":"Science (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue experiment (TP53 restoration reverses SOX2-mediated plasticity), single lab with in vivo validation","pmids":["28059768"],"is_preprint":false},{"year":2021,"finding":"The most common TP53 mutation R175H generates a neoantigen peptide presented on HLA-A at the cell surface. A bispecific single-chain diabody antibody specific for the R175H p53 peptide-HLA complex effectively activates T cells to lyse cancer cells presenting this neoantigen in vitro and in mice.","method":"Structural analysis of antibody-peptide-HLA complex, T cell activation assay, tumor cell lysis assay, mouse xenograft model","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural basis established plus functional validation in vitro and in vivo, rigorous multi-method study","pmids":["33649166"],"is_preprint":false},{"year":1995,"finding":"p53 protein functions as a site-specific transcriptional transactivator and transcriptional repressor. Oncoproteins from DNA tumor viruses (SV40 large T antigen, adenovirus E1B, HPV E6) form complexes with p53, causing its inactivation; HPV E6 uses E6AP (UBE3A) as an E3 ubiquitin ligase to promote multi-ubiquitination and degradation of p53.","method":"Co-immunoprecipitation, ubiquitination assay, transcriptional reporter assay","journal":"Pathologie-biologie","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — mechanistic findings reviewed and well-replicated across multiple labs, though this is a review/summary abstract","pmids":["7675543"],"is_preprint":false},{"year":2003,"finding":"HPV E6 from high-risk HPV types associates with E6AP (UBE3A), and this dimeric complex binds p53 and catalyzes multi-ubiquitination and proteasomal degradation of p53. Low-risk HPV E6 proteins can bind p53 but lack the ability to promote its degradation.","method":"Co-immunoprecipitation, ubiquitination assay, protein degradation assay","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — mechanism established by multiple independent labs, this review consolidates well-replicated findings","pmids":["12619117"],"is_preprint":false}],"current_model":"TP53 encodes a tetrameric transcription factor (p53) that functions as a tumor suppressor by transactivating target genes involved in cell cycle arrest, apoptosis, DNA repair, senescence, and autophagy; its stability and activity are tightly regulated by Mdm2-mediated ubiquitination and proteasomal degradation, counteracted by deubiquitinases (USP10, USP11), post-translational modifications including phosphorylation (e.g., Ser46 by a p53DINP1-associated kinase, ATM-mediated), acetylation (at K120 by NAT10, at K382 enhanced by ING4/5 via p300), beta-hydroxybutyrylation (at K120/319/370 by CBP, attenuating activity), and sumoylation/neddylation; p53 binds DNA preferentially at nucleosome edges as a pioneer factor; it produces multiple isoforms (e.g., Delta133p53, p53beta) with distinct and sometimes opposing functions including dominant-negative inhibition and promotion of invasion via EMT; in senescence, p53 drives pericentromeric heterochromatin dismantling through downregulation of TRF2; and hotspot missense mutations in its DNA-binding domain cause loss of sequence-specific DNA binding, dominant-negative effects on wild-type p53, and neomorphic gain-of-function activities including altered iron metabolism, enhanced metastasis, and remodeling of the tumor secretome."},"narrative":{"mechanistic_narrative":"TP53 encodes p53, a site-specific transcriptional transactivator and repressor that executes tumor suppression by inducing target genes governing cell cycle arrest, apoptosis, autophagy, and senescence [PMID:7675543]. p53 engages chromatin as a pioneer factor, binding preferentially at nucleosome edges where nucleosome position dominates over intrinsic site affinity, with strong nonspecific nucleosome binding facilitating chromatin access [PMID:30409772]. Its abundance is set by an antagonism between Mdm2-driven ubiquitination/degradation and counteracting deubiquitinases USP10 and USP11, which strip ubiquitin from p53 and are required for its induction after DNA damage [PMID:20096447, PMID:25471832]. Layered post-translational modifications tune activity: NAT10 acetylates p53 at K120 while also degrading Mdm2 to stabilize p53 [PMID:26882543]; ING4/ING5 bridge p53 to p300 to enhance K382 acetylation and drive p21/WAF1 transactivation and apoptosis [PMID:12750254]; a p53DINP1-associated kinase phosphorylates Ser46 to license DNA-damage-induced apoptosis [PMID:11511362]; and CBP-catalyzed β-hydroxybutyrylation at K120/K319/K370 lowers acetylation and dampens p21/PUMA induction and apoptosis [PMID:30858356]. Downstream, p53 drives an FBXO22-KDM4B-TFEB axis to upregulate basal autophagy [PMID:33706682] and dismantles pericentromeric heterochromatin during senescence by downregulating TRF2, triggering ATM-dependent breaks and an interferon response [PMID:35819196]. The gene also generates isoforms with distinct activities: Δ133p53 acts as a dominant-negative inhibitor of full-length p53 while p53β enhances target transactivation [PMID:16131611], and Δ133p53β promotes invasion and EMT independent of full-length TP53 mutation status [PMID:27630122]. Inactivation occurs through DNA tumor virus oncoproteins, including HPV E6, which recruits E6AP/UBE3A to multi-ubiquitinate and degrade p53 [PMID:7675543, PMID:12619117], and TP53 loss enables SOX2-driven lineage plasticity and therapy resistance in prostate cancer [PMID:28059768]. Hotspot mutations produce both loss of function and exploitable neoepitopes, exemplified by the R175H neoantigen presented on HLA-A and targetable by a bispecific antibody [PMID:33649166].","teleology":[{"year":1995,"claim":"Established p53 as a sequence-specific transcriptional regulator and identified its inactivation by DNA tumor virus oncoproteins, framing p53 as a degradation-controlled tumor suppressor.","evidence":"Co-IP, ubiquitination and transcriptional reporter assays summarizing viral oncoprotein interactions","pmids":["7675543"],"confidence":"Medium","gaps":["Review-level summary rather than primary mechanism","Cellular target genes not enumerated here"]},{"year":2001,"claim":"Resolved how DNA-damage signaling selects apoptosis over arrest by identifying p53DINP1 as a Ser46-phosphorylation–promoting complex required for damage-induced death.","evidence":"Differential display, antisense knockdown, kinase assay and apoptosis readouts","pmids":["11511362"],"confidence":"High","gaps":["Identity of the catalytic kinase in the complex not defined","Structural basis of Ser46 recognition unknown"]},{"year":2001,"claim":"Showed that p53 levels can be suppressed by external metabolite signaling, linking deoxycholic acid to CRM1-dependent nuclear export, ERK signaling, and proteasomal degradation of p53.","evidence":"Pharmacological dissection with proteasome, export, and ERK/PKC inhibitors plus Western blot and reporter assay","pmids":["11375905"],"confidence":"Medium","gaps":["Direct E3 ligase mediating degradation not identified","Single pathway dissection in one system"]},{"year":2003,"claim":"Defined a coactivator route to p53 acetylation by showing ING4/ING5 bridge p53 to p300 to enhance K382 acetylation and drive p21 transactivation and apoptosis.","evidence":"Reciprocal Co-IP, reporter, Western blot and apoptosis assays","pmids":["12750254"],"confidence":"Medium","gaps":["Quantitative contribution to endogenous acetylation unclear","In vivo relevance not tested"]},{"year":2003,"claim":"Detailed the HPV E6 inactivation mechanism, showing high-risk E6 recruits E6AP/UBE3A to multi-ubiquitinate and degrade p53 whereas low-risk E6 binds without degrading.","evidence":"Co-IP, ubiquitination and degradation assays consolidated across labs","pmids":["12619117"],"confidence":"Medium","gaps":["Review consolidation rather than single primary study","Structural basis of E6-E6AP-p53 ternary complex not provided here"]},{"year":2005,"claim":"Revealed that TP53 produces functionally divergent isoforms from an intron-3 alternative promoter, with p53β enhancing transactivation and Δ133p53 acting as a dominant-negative inhibitor of apoptosis.","evidence":"Reporter and promoter binding assays, apoptosis assay, RT-PCR and tissue expression","pmids":["16131611"],"confidence":"High","gaps":["Physiological regulation of isoform choice unknown","Endogenous protein-level abundance of isoforms not quantified"]},{"year":2010,"claim":"Identified USP10 as a cytoplasmic deubiquitinase that reverses Mdm2-driven p53 export/degradation and relocates to the nucleus upon ATM phosphorylation to activate p53 after DNA damage.","evidence":"Co-IP, in vitro deubiquitination, mutagenesis, fractionation and kinase assays","pmids":["20096447"],"confidence":"High","gaps":["Relative contribution versus other p53 DUBs unquantified","Determinants of nuclear translocation timing unclear"]},{"year":2014,"claim":"Added USP11 as a second deubiquitinase that complexes with and stabilizes p53 and is required for full p53 induction under DNA damage.","evidence":"Co-IP, ubiquitination assay, siRNA knockdown and Western blot","pmids":["25471832"],"confidence":"Medium","gaps":["Limited mechanistic detail beyond abstract","No reciprocal in vitro deubiquitination demonstrated"]},{"year":2016,"claim":"Showed NAT10 acetylates p53 at K120 and concurrently degrades Mdm2 via its E3 ligase activity, defining a dual stabilization mechanism activated by nucleolar-to-nucleoplasmic relocation after damage.","evidence":"Co-IP, in vitro acetylation and ubiquitination assays, fractionation, loss-of-function","pmids":["26882543"],"confidence":"High","gaps":["Trigger for NAT10 relocalization not defined","Separation of acetyltransferase versus ligase contributions to p53 stability unresolved"]},{"year":2016,"claim":"Demonstrated that the Δ133p53β isoform actively promotes invasion and EMT independent of full-length TP53 mutation status, establishing an oncogenic isoform-driven phenotype.","evidence":"Isoform-specific siRNA knockdown, invasion and EMT marker assays, clinical correlations","pmids":["27630122"],"confidence":"Medium","gaps":["Transcriptional targets mediating invasion not defined","Mechanism of isoform-specific promoter selection unknown"]},{"year":2018,"claim":"Defined the chromatin-engagement rules of p53 as a pioneer factor, showing binding is restricted to nucleosome edges with position dominating over site affinity.","evidence":"Competitive in vitro nucleosome binding with sequencing and ChIP validation","pmids":["30409772"],"confidence":"High","gaps":["How edge binding nucleates downstream coactivator recruitment unclear","Effect of cofactors on nucleosomal access not tested"]},{"year":2019,"claim":"Identified β-hydroxybutyrylation as a metabolite-driven negative modification, with CBP-catalyzed Kbhb at K120/K319/K370 reducing acetylation and blunting p21/PUMA induction and apoptosis.","evidence":"Mass spectrometry, in vitro modification, gene expression, viability assays and mouse tissue analysis","pmids":["30858356"],"confidence":"Medium","gaps":["Enzyme removing the Kbhb mark not identified","Physiological ketone conditions driving the mark in vivo not delineated"]},{"year":2021,"claim":"Connected p53 to autophagy control via transcriptional induction of FBXO22, which degrades KDM4B to derepress TFEB, a route counteracted by AKT1 phosphorylation of KDM4B.","evidence":"ChIP-seq, ubiquitination assay, fbxo22 knockout mice, overexpression and Co-IP","pmids":["33706682"],"confidence":"Medium","gaps":["Tissue-specificity of the axis not mapped","Quantitative contribution to total autophagic flux unclear"]},{"year":2021,"claim":"Showed TP53 loss drives AR-independent lineage plasticity and enzalutamide resistance through SOX2, with TP53/RB1 restoration or SOX2 inhibition reversing the phenotype.","evidence":"In vitro and in vivo prostate cancer models with TP53 restoration and SOX2 knockdown","pmids":["28059768"],"confidence":"Medium","gaps":["Direct transcriptional link between p53 and SOX2 not fully defined","Generalizability beyond prostate lineage untested"]},{"year":2021,"claim":"Established that p53 controls regulated secretion, driving adipocyte exosome and protein release (including FABP4) under lipolytic and genotoxic stress.","evidence":"p53 inhibitor and nutlin activation, p53-/- mice, secretome mass spectrometry","pmids":["37347719"],"confidence":"Medium","gaps":["Direct transcriptional effectors of secretion not identified","Mechanism linking p53 to vesicle biogenesis unclear"]},{"year":2021,"claim":"Demonstrated that the R175H hotspot mutant generates an HLA-A-presented neoantigen targetable by a bispecific antibody that redirects T cells to lyse cancer cells, establishing mutant p53 as an immunotherapeutic target.","evidence":"Structural analysis of antibody-peptide-HLA complex, T cell activation and tumor lysis assays, mouse xenografts","pmids":["33649166"],"confidence":"High","gaps":["Coverage of other hotspot neoepitopes not addressed","In-human efficacy not established here"]},{"year":2022,"claim":"Defined a p53-TRF2 axis driving selective pericentromeric heterochromatin dismantling at senescence onset via ATM-dependent breaks, KAP1/Lamin B1 release, satellite excision and interferon activation.","evidence":"Live imaging, ChIP, DNA damage assays, fractionation, cytosolic DNA detection and genetic epistasis","pmids":["35819196"],"confidence":"Medium","gaps":["Direct transcriptional control of TRF2 by p53 not fully resolved","Functional consequence of the interferon response for senescence outcome unclear"]},{"year":2023,"claim":"Showed that a structurally near-native germline variant Y107H selectively loses transactivation of a small target subset including PADI4, defining an immune-dependent p53-PADI4 tumor suppression axis.","evidence":"NMR, X-ray crystallography, transactivation assays, mouse tumor models and colony suppression","pmids":["37140445"],"confidence":"High","gaps":["Mechanism of selective promoter discrimination by Y107H unknown","Immune cell types mediating PADI4-dependent suppression not pinpointed"]},{"year":null,"claim":"How the dense layer of competing post-translational modifications, isoform ratios, and cofactor availability is integrated to specify a single p53 transcriptional output (arrest vs apoptosis vs senescence vs autophagy) in a given cell state remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking modification state to target gene selection","Quantitative interplay of stabilizing DUBs/acetylation versus repressive Kbhb not reconstituted","Isoform-resolved contributions to integrated output untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[16,2,12]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[7,16]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[7,11]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[16,2,12]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,4,2]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[10]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,11]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[11,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[15,14,17]}],"complexes":[],"partners":["MDM2","USP10","USP11","NAT10","EP300","ING4","UBE3A","TRF2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P04637","full_name":"Cellular tumor antigen p53","aliases":["Antigen NY-CO-13","Phosphoprotein p53","Tumor suppressor p53"],"length_aa":393,"mass_kda":43.7,"function":"Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:38653238, PubMed:9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P04637/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TP53","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2},{"gene":"POLR3B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TP53","total_profiled":1310},"omim":[{"mim_id":"621522","title":"SCAFFOLDING CK1-ANCHORING PROTEIN F; SACK1F","url":"https://www.omim.org/entry/621522"},{"mim_id":"621515","title":"UBIQUITIN-CONJUGATING ENZYME E2 D4; UBE2D4","url":"https://www.omim.org/entry/621515"},{"mim_id":"621451","title":"SMALL NUCLEOLAR RNA HOST GENE 12; SNHG12","url":"https://www.omim.org/entry/621451"},{"mim_id":"621436","title":"MICROCEPHALY, PROGRESSIVE, WITH SIMPLIFIED GYRAL PATTERN AND CEREBELLAR HYPOPLASIA; MGCH","url":"https://www.omim.org/entry/621436"},{"mim_id":"621430","title":"FIGNL1-INTERACTING REGULATOR OF RECOMBINATION AND MITOSIS; FIRRM","url":"https://www.omim.org/entry/621430"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TP53"},"hgnc":{"alias_symbol":["p53","LFS1"],"prev_symbol":[]},"alphafold":{"accession":"P04637","domains":[{"cath_id":"2.60.40.720","chopping":"109-287","consensus_level":"high","plddt":95.1398,"start":109,"end":287}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04637","model_url":"https://alphafold.ebi.ac.uk/files/AF-P04637-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P04637-F1-predicted_aligned_error_v6.png","plddt_mean":75.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TP53","jax_strain_url":"https://www.jax.org/strain/search?query=TP53"},"sequence":{"accession":"P04637","fasta_url":"https://rest.uniprot.org/uniprotkb/P04637.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04637/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04637"}},"corpus_meta":[{"pmid":"28059768","id":"PMC_28059768","title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28059768","citation_count":893,"is_preprint":false},{"pmid":"16131611","id":"PMC_16131611","title":"p53 isoforms can regulate p53 transcriptional activity.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16131611","citation_count":679,"is_preprint":false},{"pmid":"27328919","id":"PMC_27328919","title":"TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.","date":"2016","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/27328919","citation_count":610,"is_preprint":false},{"pmid":"20096447","id":"PMC_20096447","title":"USP10 regulates p53 localization and stability by deubiquitinating p53.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20096447","citation_count":513,"is_preprint":false},{"pmid":"29099487","id":"PMC_29099487","title":"Why are there hotspot mutations in the TP53 gene in human cancers?","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29099487","citation_count":478,"is_preprint":false},{"pmid":"33649166","id":"PMC_33649166","title":"Targeting a neoantigen derived from a common TP53 mutation.","date":"2021","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33649166","citation_count":290,"is_preprint":false},{"pmid":"11511362","id":"PMC_11511362","title":"p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11511362","citation_count":283,"is_preprint":false},{"pmid":"12619112","id":"PMC_12619112","title":"TP53 mutation in colorectal cancer.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619112","citation_count":265,"is_preprint":false},{"pmid":"12619115","id":"PMC_12619115","title":"TP53 and breast cancer.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619115","citation_count":261,"is_preprint":false},{"pmid":"17719538","id":"PMC_17719538","title":"Living with p53, dying of p53.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17719538","citation_count":256,"is_preprint":false},{"pmid":"26024390","id":"PMC_26024390","title":"TP53: an oncogene in disguise.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26024390","citation_count":253,"is_preprint":false},{"pmid":"31829441","id":"PMC_31829441","title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.","date":"2020","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31829441","citation_count":252,"is_preprint":false},{"pmid":"12750254","id":"PMC_12750254","title":"p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12750254","citation_count":240,"is_preprint":false},{"pmid":"32424350","id":"PMC_32424350","title":"Cas9 activates the p53 pathway and selects for p53-inactivating mutations.","date":"2020","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32424350","citation_count":236,"is_preprint":false},{"pmid":"27141080","id":"PMC_27141080","title":"Tumor-Suppressor Functions of the TP53 Pathway.","date":"2016","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27141080","citation_count":233,"is_preprint":false},{"pmid":"20300207","id":"PMC_20300207","title":"Clinical outcomes and correlates of TP53 mutations and cancer.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20300207","citation_count":233,"is_preprint":false},{"pmid":"12619107","id":"PMC_12619107","title":"TP53 mutations in human skin cancers.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619107","citation_count":208,"is_preprint":false},{"pmid":"12619111","id":"PMC_12619111","title":"TP53 and gastric carcinoma: a review.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619111","citation_count":193,"is_preprint":false},{"pmid":"21837677","id":"PMC_21837677","title":"Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database.","date":"2011","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21837677","citation_count":191,"is_preprint":false},{"pmid":"12619104","id":"PMC_12619104","title":"TP53 family members and human cancers.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619104","citation_count":189,"is_preprint":false},{"pmid":"12619106","id":"PMC_12619106","title":"TP53 and liver carcinogenesis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619106","citation_count":187,"is_preprint":false},{"pmid":"8718514","id":"PMC_8718514","title":"Germline mutations in the TP53 gene.","date":"1995","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/8718514","citation_count":171,"is_preprint":false},{"pmid":"26882543","id":"PMC_26882543","title":"NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/26882543","citation_count":168,"is_preprint":false},{"pmid":"32203095","id":"PMC_32203095","title":"Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.","date":"2020","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/32203095","citation_count":161,"is_preprint":false},{"pmid":"7523212","id":"PMC_7523212","title":"TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.","date":"1994","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/7523212","citation_count":158,"is_preprint":false},{"pmid":"11900880","id":"PMC_11900880","title":"TP53: a key gene in human cancer.","date":"2002","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/11900880","citation_count":150,"is_preprint":false},{"pmid":"12619117","id":"PMC_12619117","title":"The role of TP53 in Cervical carcinogenesis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619117","citation_count":142,"is_preprint":false},{"pmid":"30858356","id":"PMC_30858356","title":"p53 β-hydroxybutyrylation attenuates p53 activity.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30858356","citation_count":135,"is_preprint":false},{"pmid":"34878954","id":"PMC_34878954","title":"Autophagy inhibition mediated by MCOLN1/TRPML1 suppresses cancer metastasis via regulating a ROS-driven TP53/p53 pathway.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34878954","citation_count":130,"is_preprint":false},{"pmid":"12619114","id":"PMC_12619114","title":"TP53 and ovarian cancer.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619114","citation_count":128,"is_preprint":false},{"pmid":"35332311","id":"PMC_35332311","title":"Should mutant TP53 be targeted for cancer therapy?","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35332311","citation_count":119,"is_preprint":false},{"pmid":"19918835","id":"PMC_19918835","title":"Massively regulated genes: the example of TP53.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19918835","citation_count":111,"is_preprint":false},{"pmid":"25896519","id":"PMC_25896519","title":"Germline TP53 variants and susceptibility to osteosarcoma.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/25896519","citation_count":107,"is_preprint":false},{"pmid":"30907951","id":"PMC_30907951","title":"Understanding p53 functions through p53 antibodies.","date":"2019","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30907951","citation_count":102,"is_preprint":false},{"pmid":"36766853","id":"PMC_36766853","title":"The Role of TP53 in Adaptation and Evolution.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36766853","citation_count":98,"is_preprint":false},{"pmid":"27885271","id":"PMC_27885271","title":"p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27885271","citation_count":92,"is_preprint":false},{"pmid":"23355100","id":"PMC_23355100","title":"Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.","date":"2013","source":"Molecular diagnosis & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23355100","citation_count":80,"is_preprint":false},{"pmid":"20876940","id":"PMC_20876940","title":"TP53 and MTOR crosstalk to regulate cellular senescence.","date":"2010","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/20876940","citation_count":76,"is_preprint":false},{"pmid":"27449973","id":"PMC_27449973","title":"Clinical Outcomes of TP53 Mutations in Cancers.","date":"2016","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27449973","citation_count":74,"is_preprint":false},{"pmid":"11375905","id":"PMC_11375905","title":"Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation.","date":"2001","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11375905","citation_count":74,"is_preprint":false},{"pmid":"35658479","id":"PMC_35658479","title":"TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.","date":"2022","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35658479","citation_count":72,"is_preprint":false},{"pmid":"33194757","id":"PMC_33194757","title":"Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33194757","citation_count":66,"is_preprint":false},{"pmid":"7905277","id":"PMC_7905277","title":"TP53 allele loss, mutations and expression in malignant melanoma.","date":"1994","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7905277","citation_count":65,"is_preprint":false},{"pmid":"38666907","id":"PMC_38666907","title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38666907","citation_count":63,"is_preprint":false},{"pmid":"12619110","id":"PMC_12619110","title":"TP53 and head and neck neoplasms.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619110","citation_count":62,"is_preprint":false},{"pmid":"30687640","id":"PMC_30687640","title":"Deregulation and Targeting of TP53 Pathway in Multiple Myeloma.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30687640","citation_count":60,"is_preprint":false},{"pmid":"17188467","id":"PMC_17188467","title":"The p53 network: p53 and its downstream genes.","date":"2006","source":"Colloids and surfaces. B, Biointerfaces","url":"https://pubmed.ncbi.nlm.nih.gov/17188467","citation_count":59,"is_preprint":false},{"pmid":"24395704","id":"PMC_24395704","title":"Mutant TP53 posttranslational modifications: challenges and opportunities.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24395704","citation_count":56,"is_preprint":false},{"pmid":"27630122","id":"PMC_27630122","title":"TP53 drives invasion through expression of its Δ133p53β variant.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27630122","citation_count":56,"is_preprint":false},{"pmid":"34503094","id":"PMC_34503094","title":"TP53 in Biology and Treatment of Osteosarcoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503094","citation_count":55,"is_preprint":false},{"pmid":"10580847","id":"PMC_10580847","title":"Is TP53 dysfunction required for BRCA1-associated carcinogenesis?","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10580847","citation_count":55,"is_preprint":false},{"pmid":"27582538","id":"PMC_27582538","title":"TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27582538","citation_count":53,"is_preprint":false},{"pmid":"34389799","id":"PMC_34389799","title":"Spontaneous and inherited TP53 genetic alterations.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34389799","citation_count":52,"is_preprint":false},{"pmid":"32748433","id":"PMC_32748433","title":"p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.","date":"2020","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32748433","citation_count":52,"is_preprint":false},{"pmid":"32630614","id":"PMC_32630614","title":"Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32630614","citation_count":51,"is_preprint":false},{"pmid":"25471832","id":"PMC_25471832","title":"USP11 regulates p53 stability by deubiquitinating p53.","date":"2014","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/25471832","citation_count":51,"is_preprint":false},{"pmid":"30466751","id":"PMC_30466751","title":"Patterns of mutations in TP53 mutated AML.","date":"2018","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30466751","citation_count":50,"is_preprint":false},{"pmid":"27003724","id":"PMC_27003724","title":"TP53 mutation, mitochondria and cancer.","date":"2016","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/27003724","citation_count":48,"is_preprint":false},{"pmid":"32075247","id":"PMC_32075247","title":"p53's Extended Reach: The Mutant p53 Secretome.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32075247","citation_count":48,"is_preprint":false},{"pmid":"12673364","id":"PMC_12673364","title":"TP53 and mutations in human cancer.","date":"2003","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/12673364","citation_count":47,"is_preprint":false},{"pmid":"30409772","id":"PMC_30409772","title":"Defining TP53 pioneering capabilities with competitive nucleosome binding assays.","date":"2018","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/30409772","citation_count":46,"is_preprint":false},{"pmid":"31776983","id":"PMC_31776983","title":"TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy.","date":"2019","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/31776983","citation_count":45,"is_preprint":false},{"pmid":"32703491","id":"PMC_32703491","title":"Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer.","date":"2020","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/32703491","citation_count":44,"is_preprint":false},{"pmid":"8013000","id":"PMC_8013000","title":"The role of TP53 in breast cancer development.","date":"1993","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/8013000","citation_count":43,"is_preprint":false},{"pmid":"26898759","id":"PMC_26898759","title":"TRIMming p53's anticancer activity.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26898759","citation_count":40,"is_preprint":false},{"pmid":"34017087","id":"PMC_34017087","title":"TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34017087","citation_count":40,"is_preprint":false},{"pmid":"36471402","id":"PMC_36471402","title":"p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.","date":"2022","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36471402","citation_count":39,"is_preprint":false},{"pmid":"24630986","id":"PMC_24630986","title":"Plk1-targeted therapies in TP53- or RAS-mutated cancer.","date":"2014","source":"Mutation research. Reviews in mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/24630986","citation_count":39,"is_preprint":false},{"pmid":"39443700","id":"PMC_39443700","title":"TP53: the unluckiest of genes?","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/39443700","citation_count":38,"is_preprint":false},{"pmid":"29307398","id":"PMC_29307398","title":"p53 and reproduction.","date":"2018","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/29307398","citation_count":36,"is_preprint":false},{"pmid":"7597286","id":"PMC_7597286","title":"Mutation and expression of TP53 in malignant melanomas.","date":"1995","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7597286","citation_count":36,"is_preprint":false},{"pmid":"9723023","id":"PMC_9723023","title":"Correlation of TP53 mutations and p53 expression in ovarian tumors.","date":"1998","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9723023","citation_count":36,"is_preprint":false},{"pmid":"17386256","id":"PMC_17386256","title":"Mdm2: p53's lifesaver?","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17386256","citation_count":35,"is_preprint":false},{"pmid":"37748270","id":"PMC_37748270","title":"TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.","date":"2023","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37748270","citation_count":33,"is_preprint":false},{"pmid":"15922892","id":"PMC_15922892","title":"Mutation and methylation analysis of TP53 in adrenal carcinogenesis.","date":"2005","source":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15922892","citation_count":33,"is_preprint":false},{"pmid":"9038605","id":"PMC_9038605","title":"Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas.","date":"1996","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/9038605","citation_count":31,"is_preprint":false},{"pmid":"33514515","id":"PMC_33514515","title":"Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33514515","citation_count":30,"is_preprint":false},{"pmid":"27918441","id":"PMC_27918441","title":"TP53/MicroRNA Interplay in Hepatocellular Carcinoma.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27918441","citation_count":29,"is_preprint":false},{"pmid":"21779516","id":"PMC_21779516","title":"TP53-Associated Pediatric Malignancies.","date":"2011","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21779516","citation_count":28,"is_preprint":false},{"pmid":"29900037","id":"PMC_29900037","title":"Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29900037","citation_count":26,"is_preprint":false},{"pmid":"27813088","id":"PMC_27813088","title":"Nutlin-3a selects for cells harbouring TP53 mutations.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27813088","citation_count":26,"is_preprint":false},{"pmid":"37140445","id":"PMC_37140445","title":"An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression.","date":"2023","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37140445","citation_count":25,"is_preprint":false},{"pmid":"36485102","id":"PMC_36485102","title":"Transplant for TP53-mutated MDS and AML: because we can or because we should?","date":"2022","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/36485102","citation_count":24,"is_preprint":false},{"pmid":"29769598","id":"PMC_29769598","title":"Germline mutation in the TP53 gene in uveal melanoma.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29769598","citation_count":24,"is_preprint":false},{"pmid":"12619109","id":"PMC_12619109","title":"TP53 mutations in workers exposed to occupational carcinogens.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12619109","citation_count":22,"is_preprint":false},{"pmid":"32089220","id":"PMC_32089220","title":"Targeting TP53 Mutations in Myelodysplastic Syndromes.","date":"2019","source":"Hematology/oncology clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/32089220","citation_count":21,"is_preprint":false},{"pmid":"33706682","id":"PMC_33706682","title":"TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33706682","citation_count":20,"is_preprint":false},{"pmid":"36788081","id":"PMC_36788081","title":"p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36788081","citation_count":20,"is_preprint":false},{"pmid":"31500291","id":"PMC_31500291","title":"Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism.","date":"2019","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/31500291","citation_count":19,"is_preprint":false},{"pmid":"10448303","id":"PMC_10448303","title":"Abnormal expression or mutation of TP53 and HPV in vulvar cancer.","date":"1999","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/10448303","citation_count":19,"is_preprint":false},{"pmid":"24489863","id":"PMC_24489863","title":"BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489863","citation_count":19,"is_preprint":false},{"pmid":"34771553","id":"PMC_34771553","title":"TP53 in Myelodysplastic Syndromes.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34771553","citation_count":17,"is_preprint":false},{"pmid":"30174725","id":"PMC_30174725","title":"Surgery for BRCA, TP53 and PALB2: a literature review.","date":"2018","source":"Ecancermedicalscience","url":"https://pubmed.ncbi.nlm.nih.gov/30174725","citation_count":17,"is_preprint":false},{"pmid":"17472413","id":"PMC_17472413","title":"INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.","date":"2007","source":"Drugs in R&D","url":"https://pubmed.ncbi.nlm.nih.gov/17472413","citation_count":17,"is_preprint":false},{"pmid":"35819196","id":"PMC_35819196","title":"Selective pericentromeric heterochromatin dismantling caused by TP53 activation during senescence.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35819196","citation_count":17,"is_preprint":false},{"pmid":"24014294","id":"PMC_24014294","title":"TP53 aberrations in chronic lymphocytic leukemia.","date":"2013","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/24014294","citation_count":16,"is_preprint":false},{"pmid":"37347719","id":"PMC_37347719","title":"TP53/p53 Facilitates Stress-Induced Exosome and Protein Secretion by Adipocytes.","date":"2023","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/37347719","citation_count":15,"is_preprint":false},{"pmid":"28679301","id":"PMC_28679301","title":"TP53 in adult acute lymphoblastic leukemia.","date":"2017","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/28679301","citation_count":15,"is_preprint":false},{"pmid":"30712002","id":"PMC_30712002","title":"Relevance of TP53 for CLL diagnostics.","date":"2019","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30712002","citation_count":14,"is_preprint":false},{"pmid":"7675543","id":"PMC_7675543","title":"[P53 and cancers].","date":"1995","source":"Pathologie-biologie","url":"https://pubmed.ncbi.nlm.nih.gov/7675543","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44388,"output_tokens":4478,"usd":0.100167,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12459,"output_tokens":5429,"usd":0.09901,"stage2_stop_reason":"end_turn"},"total_usd":0.199177,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"USP10, a cytoplasmic ubiquitin-specific protease, deubiquitinates p53, reversing Mdm2-induced p53 nuclear export and degradation. After DNA damage, ATM-mediated phosphorylation of USP10 at Thr42 and Ser337 stabilizes USP10 and triggers a fraction of USP10 to translocate to the nucleus to activate p53.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deubiquitination assay, site-directed mutagenesis, subcellular fractionation, kinase assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, in vitro assay, mutagenesis, fractionation) in a single rigorous study published in Cell\",\n      \"pmids\": [\"20096447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NAT10 acetylates p53 at K120 and stabilizes p53 by counteracting Mdm2. Additionally, NAT10 promotes Mdm2 degradation via its intrinsic E3 ubiquitin ligase activity. After DNA damage, NAT10 translocates from the nucleolus to the nucleoplasm to activate p53-mediated cell cycle control and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro acetylation assay, ubiquitination assay, subcellular fractionation, loss-of-function experiments\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (Co-IP, in vitro enzymatic assays, localization) in single lab study\",\n      \"pmids\": [\"26882543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The human p53 gene contains an alternative promoter in intron 3 and produces multiple splice variant isoforms. The p53beta isoform can bind differentially to promoters and enhance p53 target gene expression in a promoter-dependent manner, while Delta133p53 acts as a dominant-negative inhibitor of full-length p53, suppressing p53-mediated apoptosis.\",\n      \"method\": \"Reporter gene assay, promoter binding assay, apoptosis assay, RT-PCR, tissue expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional assays (reporter, binding, apoptosis) with isoform-specific constructs, replicated across multiple experimental systems\",\n      \"pmids\": [\"16131611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"p53 is modified by beta-hydroxybutyrylation (Kbhb) at lysines 120, 319, and 370, catalyzed by CBP. This modification results in lower levels of p53 acetylation, reduced expression of p53 downstream genes p21 and PUMA, and reduced cell growth arrest and apoptosis under p53-activating conditions.\",\n      \"method\": \"Mass spectrometry, in vitro modification assay, Western blot, gene expression analysis, cell viability assay, mouse tissue analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (MS, in vitro assay, cellular and in vivo readouts) in single lab study\",\n      \"pmids\": [\"30858356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"p29ING4 and p28ING5 physically interact with both p53 and p300 (a histone acetyltransferase), enhance p53 acetylation at Lys-382, activate the p21/WAF1 promoter, and induce apoptosis in a p53-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assay, Western blot, apoptosis assay, colony formation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional assays (reporter, apoptosis) in single lab study\",\n      \"pmids\": [\"12750254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p53DINP1 is a p53-inducible gene whose protein product forms a complex that phosphorylates p53 at Ser46. Antisense inhibition of p53DINP1 blocks DNA damage-induced Ser46 phosphorylation, p53AIP1 induction, and apoptosis. Overexpression of p53DINP1 synergistically enhances Ser46 phosphorylation and apoptotic cell death with DNA damage.\",\n      \"method\": \"Differential display, antisense oligonucleotide knockdown, kinase assay, co-immunoprecipitation, apoptosis assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — kinase assay establishing phosphorylation, combined with loss-of-function (antisense) and gain-of-function experiments with defined readouts\",\n      \"pmids\": [\"11511362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"USP11, an ubiquitin-specific protease, forms specific complexes with p53 and stabilizes p53 by deubiquitinating it. Down-regulation of USP11 dramatically attenuates p53 induction in response to DNA damage stress.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, Western blot, siRNA knockdown\",\n      \"journal\": \"Journal of Zhejiang University. Science. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — Co-IP and functional knockdown from single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"25471832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TP53 functions as a pioneer transcription factor with binding limited to nucleosome edges; significant binding inhibition occurs within 50 bp of the nucleosome dyad. Binding site affinity affects TP53 binding only at equivalent nucleosomal positions; otherwise, nucleosome position takes precedence. TP53 has strong nonspecific nucleosome binding facilitating chromatin interaction.\",\n      \"method\": \"Competitive in vitro nucleosome binding assay, next-generation sequencing, cell line ChIP validation\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with quantitative sequencing readout plus in-cell validation, single lab but orthogonal methods\",\n      \"pmids\": [\"30409772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The p53 isoform Delta133p53beta promotes cancer cell invasion and epithelial-mesenchymal transition (EMT) regardless of full-length TP53 mutation status. Endogenous mutant Delta133p53beta depletion prevents invasiveness without affecting full-length mutant p53 expression.\",\n      \"method\": \"siRNA knockdown, invasion assay, EMT marker analysis, clinical correlations\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific knockdown with defined invasion phenotype, validated in multiple cell lines and clinical data\",\n      \"pmids\": [\"27630122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Deoxycholic acid (DCA) suppresses p53 protein levels by stimulating proteasome-mediated p53 degradation. This process requires nuclear export via CRM1 and is mediated in part through ERK signaling, as ERK pathway blockade (but not PKC blockade) prevents DCA-induced p53 suppression.\",\n      \"method\": \"Proteasome inhibitor (lactacystin), nuclear export inhibitor (leptomycin B), ERK/PKC pathway inhibitors, Western blot, reporter assay\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with multiple specific inhibitors establishing pathway mechanism, single lab\",\n      \"pmids\": [\"11375905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TP53 transcriptionally induces FBXO22, which ubiquitinates KDM4B (complexed with MYC-NCOR1 suppressors) for degradation, leading to transcriptional induction of TFEB and upregulation of basal autophagy. AKT1 activation counteracts this process through phosphorylation of KDM4B, inhibiting FBXO22-mediated ubiquitination.\",\n      \"method\": \"ChIP-seq, ubiquitination assay, genetic knockout (fbxo22 mice), overexpression studies, co-immunoprecipitation\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including in vivo model, ChIP-seq, and ubiquitination assay in single lab\",\n      \"pmids\": [\"33706682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"At the onset of senescence, TP53 activation leads to downregulation of TRF2 at pericentromeres, which triggers ATM-mediated DNA breaks, heterochromatin decondensation (release of KAP1 and Lamin B1), recombination, satellite DNA excision, and interferon response activation. This TP53-TRF2 axis drives selective pericentromeric heterochromatin dismantling during senescence.\",\n      \"method\": \"Live cell imaging, ChIP, DNA damage assays, fractionation, cytosolic DNA detection (cGAS), genetic epistasis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis and multiple mechanistic readouts in single lab establishing pathway order\",\n      \"pmids\": [\"35819196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A rare African-specific TP53 germline variant Y107H is structurally similar to wild-type p53 (by NMR and crystal structure) but is selectively impaired for transactivation of a small subset of target genes including PADI4. PADI4 is itself tumor suppressive and requires an intact immune system for tumor suppression, defining a p53-PADI4 immune-modulatory tumor suppression axis.\",\n      \"method\": \"NMR spectroscopy, X-ray crystallography, transactivation assays, mouse tumor models, colony suppression assay\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus NMR plus functional transactivation assays plus in vivo mouse tumor models establishing a specific mechanistic pathway\",\n      \"pmids\": [\"37140445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TP53-dependent activation of p53 in adipocytes facilitates exosome and protein secretion (including FABP4 and AdEV proteins) in response to lipolytic stimulation and genotoxic stress. Pharmacologic inhibition or genetic loss of p53 attenuates adipocyte-derived extracellular vesicle and protein secretion.\",\n      \"method\": \"p53 inhibitor treatment, MDM2 antagonist (nutlin) activation, p53-/- mouse model, mass spectrometry of secretome, Western blot\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (p53-/- mice) and pharmacological (nutlin, inhibitor) approaches with mass spectrometry validation in single lab\",\n      \"pmids\": [\"37347719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TP53 loss enables cancer cell lineage plasticity from AR-dependent luminal epithelial to AR-independent basal-like cells in prostate cancer, mediated through increased SOX2 expression. Restoring TP53 function (together with RB1) or inhibiting SOX2 reverses this lineage plasticity and enzalutamide resistance.\",\n      \"method\": \"In vitro and in vivo prostate cancer models, TP53/RB1 restoration, SOX2 knockdown, lineage marker analysis\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue experiment (TP53 restoration reverses SOX2-mediated plasticity), single lab with in vivo validation\",\n      \"pmids\": [\"28059768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The most common TP53 mutation R175H generates a neoantigen peptide presented on HLA-A at the cell surface. A bispecific single-chain diabody antibody specific for the R175H p53 peptide-HLA complex effectively activates T cells to lyse cancer cells presenting this neoantigen in vitro and in mice.\",\n      \"method\": \"Structural analysis of antibody-peptide-HLA complex, T cell activation assay, tumor cell lysis assay, mouse xenograft model\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural basis established plus functional validation in vitro and in vivo, rigorous multi-method study\",\n      \"pmids\": [\"33649166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"p53 protein functions as a site-specific transcriptional transactivator and transcriptional repressor. Oncoproteins from DNA tumor viruses (SV40 large T antigen, adenovirus E1B, HPV E6) form complexes with p53, causing its inactivation; HPV E6 uses E6AP (UBE3A) as an E3 ubiquitin ligase to promote multi-ubiquitination and degradation of p53.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, transcriptional reporter assay\",\n      \"journal\": \"Pathologie-biologie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic findings reviewed and well-replicated across multiple labs, though this is a review/summary abstract\",\n      \"pmids\": [\"7675543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HPV E6 from high-risk HPV types associates with E6AP (UBE3A), and this dimeric complex binds p53 and catalyzes multi-ubiquitination and proteasomal degradation of p53. Low-risk HPV E6 proteins can bind p53 but lack the ability to promote its degradation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, protein degradation assay\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanism established by multiple independent labs, this review consolidates well-replicated findings\",\n      \"pmids\": [\"12619117\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TP53 encodes a tetrameric transcription factor (p53) that functions as a tumor suppressor by transactivating target genes involved in cell cycle arrest, apoptosis, DNA repair, senescence, and autophagy; its stability and activity are tightly regulated by Mdm2-mediated ubiquitination and proteasomal degradation, counteracted by deubiquitinases (USP10, USP11), post-translational modifications including phosphorylation (e.g., Ser46 by a p53DINP1-associated kinase, ATM-mediated), acetylation (at K120 by NAT10, at K382 enhanced by ING4/5 via p300), beta-hydroxybutyrylation (at K120/319/370 by CBP, attenuating activity), and sumoylation/neddylation; p53 binds DNA preferentially at nucleosome edges as a pioneer factor; it produces multiple isoforms (e.g., Delta133p53, p53beta) with distinct and sometimes opposing functions including dominant-negative inhibition and promotion of invasion via EMT; in senescence, p53 drives pericentromeric heterochromatin dismantling through downregulation of TRF2; and hotspot missense mutations in its DNA-binding domain cause loss of sequence-specific DNA binding, dominant-negative effects on wild-type p53, and neomorphic gain-of-function activities including altered iron metabolism, enhanced metastasis, and remodeling of the tumor secretome.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TP53 encodes p53, a site-specific transcriptional transactivator and repressor that executes tumor suppression by inducing target genes governing cell cycle arrest, apoptosis, autophagy, and senescence [#16]. p53 engages chromatin as a pioneer factor, binding preferentially at nucleosome edges where nucleosome position dominates over intrinsic site affinity, with strong nonspecific nucleosome binding facilitating chromatin access [#7]. Its abundance is set by an antagonism between Mdm2-driven ubiquitination/degradation and counteracting deubiquitinases USP10 and USP11, which strip ubiquitin from p53 and are required for its induction after DNA damage [#0, #6]. Layered post-translational modifications tune activity: NAT10 acetylates p53 at K120 while also degrading Mdm2 to stabilize p53 [#1]; ING4/ING5 bridge p53 to p300 to enhance K382 acetylation and drive p21/WAF1 transactivation and apoptosis [#4]; a p53DINP1-associated kinase phosphorylates Ser46 to license DNA-damage-induced apoptosis [#5]; and CBP-catalyzed β-hydroxybutyrylation at K120/K319/K370 lowers acetylation and dampens p21/PUMA induction and apoptosis [#3]. Downstream, p53 drives an FBXO22-KDM4B-TFEB axis to upregulate basal autophagy [#10] and dismantles pericentromeric heterochromatin during senescence by downregulating TRF2, triggering ATM-dependent breaks and an interferon response [#11]. The gene also generates isoforms with distinct activities: Δ133p53 acts as a dominant-negative inhibitor of full-length p53 while p53β enhances target transactivation [#2], and Δ133p53β promotes invasion and EMT independent of full-length TP53 mutation status [#8]. Inactivation occurs through DNA tumor virus oncoproteins, including HPV E6, which recruits E6AP/UBE3A to multi-ubiquitinate and degrade p53 [#16, #17], and TP53 loss enables SOX2-driven lineage plasticity and therapy resistance in prostate cancer [#14]. Hotspot mutations produce both loss of function and exploitable neoepitopes, exemplified by the R175H neoantigen presented on HLA-A and targetable by a bispecific antibody [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established p53 as a sequence-specific transcriptional regulator and identified its inactivation by DNA tumor virus oncoproteins, framing p53 as a degradation-controlled tumor suppressor.\",\n      \"evidence\": \"Co-IP, ubiquitination and transcriptional reporter assays summarizing viral oncoprotein interactions\",\n      \"pmids\": [\"7675543\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level summary rather than primary mechanism\", \"Cellular target genes not enumerated here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved how DNA-damage signaling selects apoptosis over arrest by identifying p53DINP1 as a Ser46-phosphorylation–promoting complex required for damage-induced death.\",\n      \"evidence\": \"Differential display, antisense knockdown, kinase assay and apoptosis readouts\",\n      \"pmids\": [\"11511362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the catalytic kinase in the complex not defined\", \"Structural basis of Ser46 recognition unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that p53 levels can be suppressed by external metabolite signaling, linking deoxycholic acid to CRM1-dependent nuclear export, ERK signaling, and proteasomal degradation of p53.\",\n      \"evidence\": \"Pharmacological dissection with proteasome, export, and ERK/PKC inhibitors plus Western blot and reporter assay\",\n      \"pmids\": [\"11375905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct E3 ligase mediating degradation not identified\", \"Single pathway dissection in one system\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined a coactivator route to p53 acetylation by showing ING4/ING5 bridge p53 to p300 to enhance K382 acetylation and drive p21 transactivation and apoptosis.\",\n      \"evidence\": \"Reciprocal Co-IP, reporter, Western blot and apoptosis assays\",\n      \"pmids\": [\"12750254\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution to endogenous acetylation unclear\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Detailed the HPV E6 inactivation mechanism, showing high-risk E6 recruits E6AP/UBE3A to multi-ubiquitinate and degrade p53 whereas low-risk E6 binds without degrading.\",\n      \"evidence\": \"Co-IP, ubiquitination and degradation assays consolidated across labs\",\n      \"pmids\": [\"12619117\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review consolidation rather than single primary study\", \"Structural basis of E6-E6AP-p53 ternary complex not provided here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed that TP53 produces functionally divergent isoforms from an intron-3 alternative promoter, with p53β enhancing transactivation and Δ133p53 acting as a dominant-negative inhibitor of apoptosis.\",\n      \"evidence\": \"Reporter and promoter binding assays, apoptosis assay, RT-PCR and tissue expression\",\n      \"pmids\": [\"16131611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological regulation of isoform choice unknown\", \"Endogenous protein-level abundance of isoforms not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified USP10 as a cytoplasmic deubiquitinase that reverses Mdm2-driven p53 export/degradation and relocates to the nucleus upon ATM phosphorylation to activate p53 after DNA damage.\",\n      \"evidence\": \"Co-IP, in vitro deubiquitination, mutagenesis, fractionation and kinase assays\",\n      \"pmids\": [\"20096447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution versus other p53 DUBs unquantified\", \"Determinants of nuclear translocation timing unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Added USP11 as a second deubiquitinase that complexes with and stabilizes p53 and is required for full p53 induction under DNA damage.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, siRNA knockdown and Western blot\",\n      \"pmids\": [\"25471832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited mechanistic detail beyond abstract\", \"No reciprocal in vitro deubiquitination demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed NAT10 acetylates p53 at K120 and concurrently degrades Mdm2 via its E3 ligase activity, defining a dual stabilization mechanism activated by nucleolar-to-nucleoplasmic relocation after damage.\",\n      \"evidence\": \"Co-IP, in vitro acetylation and ubiquitination assays, fractionation, loss-of-function\",\n      \"pmids\": [\"26882543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for NAT10 relocalization not defined\", \"Separation of acetyltransferase versus ligase contributions to p53 stability unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that the Δ133p53β isoform actively promotes invasion and EMT independent of full-length TP53 mutation status, establishing an oncogenic isoform-driven phenotype.\",\n      \"evidence\": \"Isoform-specific siRNA knockdown, invasion and EMT marker assays, clinical correlations\",\n      \"pmids\": [\"27630122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional targets mediating invasion not defined\", \"Mechanism of isoform-specific promoter selection unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the chromatin-engagement rules of p53 as a pioneer factor, showing binding is restricted to nucleosome edges with position dominating over site affinity.\",\n      \"evidence\": \"Competitive in vitro nucleosome binding with sequencing and ChIP validation\",\n      \"pmids\": [\"30409772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How edge binding nucleates downstream coactivator recruitment unclear\", \"Effect of cofactors on nucleosomal access not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified β-hydroxybutyrylation as a metabolite-driven negative modification, with CBP-catalyzed Kbhb at K120/K319/K370 reducing acetylation and blunting p21/PUMA induction and apoptosis.\",\n      \"evidence\": \"Mass spectrometry, in vitro modification, gene expression, viability assays and mouse tissue analysis\",\n      \"pmids\": [\"30858356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzyme removing the Kbhb mark not identified\", \"Physiological ketone conditions driving the mark in vivo not delineated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected p53 to autophagy control via transcriptional induction of FBXO22, which degrades KDM4B to derepress TFEB, a route counteracted by AKT1 phosphorylation of KDM4B.\",\n      \"evidence\": \"ChIP-seq, ubiquitination assay, fbxo22 knockout mice, overexpression and Co-IP\",\n      \"pmids\": [\"33706682\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specificity of the axis not mapped\", \"Quantitative contribution to total autophagic flux unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed TP53 loss drives AR-independent lineage plasticity and enzalutamide resistance through SOX2, with TP53/RB1 restoration or SOX2 inhibition reversing the phenotype.\",\n      \"evidence\": \"In vitro and in vivo prostate cancer models with TP53 restoration and SOX2 knockdown\",\n      \"pmids\": [\"28059768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional link between p53 and SOX2 not fully defined\", \"Generalizability beyond prostate lineage untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that p53 controls regulated secretion, driving adipocyte exosome and protein release (including FABP4) under lipolytic and genotoxic stress.\",\n      \"evidence\": \"p53 inhibitor and nutlin activation, p53-/- mice, secretome mass spectrometry\",\n      \"pmids\": [\"37347719\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional effectors of secretion not identified\", \"Mechanism linking p53 to vesicle biogenesis unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that the R175H hotspot mutant generates an HLA-A-presented neoantigen targetable by a bispecific antibody that redirects T cells to lyse cancer cells, establishing mutant p53 as an immunotherapeutic target.\",\n      \"evidence\": \"Structural analysis of antibody-peptide-HLA complex, T cell activation and tumor lysis assays, mouse xenografts\",\n      \"pmids\": [\"33649166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coverage of other hotspot neoepitopes not addressed\", \"In-human efficacy not established here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a p53-TRF2 axis driving selective pericentromeric heterochromatin dismantling at senescence onset via ATM-dependent breaks, KAP1/Lamin B1 release, satellite excision and interferon activation.\",\n      \"evidence\": \"Live imaging, ChIP, DNA damage assays, fractionation, cytosolic DNA detection and genetic epistasis\",\n      \"pmids\": [\"35819196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional control of TRF2 by p53 not fully resolved\", \"Functional consequence of the interferon response for senescence outcome unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed that a structurally near-native germline variant Y107H selectively loses transactivation of a small target subset including PADI4, defining an immune-dependent p53-PADI4 tumor suppression axis.\",\n      \"evidence\": \"NMR, X-ray crystallography, transactivation assays, mouse tumor models and colony suppression\",\n      \"pmids\": [\"37140445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selective promoter discrimination by Y107H unknown\", \"Immune cell types mediating PADI4-dependent suppression not pinpointed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the dense layer of competing post-translational modifications, isoform ratios, and cofactor availability is integrated to specify a single p53 transcriptional output (arrest vs apoptosis vs senescence vs autophagy) in a given cell state remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking modification state to target gene selection\", \"Quantitative interplay of stabilizing DUBs/acetylation versus repressive Kbhb not reconstituted\", \"Isoform-resolved contributions to integrated output untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [16, 2, 12]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [7, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [7, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [16, 2, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 4, 2]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [11, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [15, 14, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MDM2\", \"USP10\", \"USP11\", \"NAT10\", \"EP300\", \"ING4\", \"UBE3A\", \"TRF2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}